Guardion Health Sciences, Inc. (GHSI) |
|
6 -0.14 (-2.28%)
|
06-09 12:49 |
|
Open: |
6.14 |
Pre. Close: |
6.14 |
|
High:
|
6.14 |
Low:
|
6 |
|
Volume:
|
12,087 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 12:45:11 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 8.24  One year: 9.07 |
| Support: |
Support1: 5.9 Support2: 4.91 |
| Resistance: |
Resistance1: 7.05 Resistance2: 7.76 |
| Pivot: |
6.31 |
| Moving Average: |
MA(5): 6.07 MA(20): 6.28
MA(100): 6.3 MA(250): 7.16 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 6.4 %D(3): 11 |
| RSI: |
RSI(14): 46.2 |
| 52-week: |
High: 10.5 Low: 4.65 |
| Average Vol(K): |
3-Month: 20 (K) 10-Days: 21 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GHSI ] has closed above bottom band by 22.4%. Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.78 - 7.81 |
7.81 - 7.85 |
|
Low:
|
5.93 - 5.96 |
5.96 - 5.99 |
|
Close:
|
6.09 - 6.14 |
6.14 - 6.19 |
|
Company Description |
|
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California. |
Headline News |
Thu, 08 Jun 2023
Should You Accumulate Guardion Health Sciences Inc (GHSI) in Drug Manufacturers - Specialty & Generic Industry? - InvestorsObserver
Tue, 30 May 2023
Guardion Health Sciences Appoints Jan Hall as CEO - citybiz
Mon, 15 May 2023
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023 - Yahoo Finance
Wed, 19 Apr 2023
Guardion Health Sciences, Inc.'s (NASDAQ:GHSI) Shares Leap 29% Yet They're Still Not Telling The Full Story - Yahoo Finance
Mon, 06 Mar 2023
Guardion Health Sciences Hires Alantra, LLC as its Financial ... - GlobeNewswire
Tue, 24 Jan 2023
Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
1 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
22.5 (%) |
|
% Held by Institutions
|
5.8 (%) |
|
Shares Short
|
123 (K) |
|
Shares Short P.Month
|
127 (K) |
Stock Financials |
|
EPS
|
-6.89 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.69 |
|
Profit Margin (%)
|
-76.7 |
|
Operating Margin (%)
|
-52.3 |
|
Return on Assets (ttm)
|
-16.8 |
|
Return on Equity (ttm)
|
-47.5 |
|
Qtrly Rev. Growth
|
33.5 |
|
Gross Profit (p.s.)
|
3.55 |
|
Sales Per Share
|
9.33 |
|
EBITDA (p.s.)
|
-4.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-7 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
-0.88 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.89 |
|
Price to Sales
|
0.64 |
|
Price to Cash Flow
|
-1.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
